In CHC patients, from day 0 to day 2 of pegIFN/ribavirin therapy, a higher inducibility of ISG15 (observed in patients who were classified as ISG15lo at baseline) correlated with a stronger persistence of Tregs under IFN exposure in vivo. This evidence concerns the gene IFNA1 and cryohydrocytosis.